Candel Therapeutics, Inc. key statistics and ratios
In fiscal 2022, Candel Therapeutics, Inc. had return on equity of -33.6%, an operating margin of -27777.6%, debt equal to 1.4% of equity and a current ratio of 12.81. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 |
|---|---|---|---|
| Operating margin | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | <−999% |
| Return on equity | — | −178.1% | −33.6% |
| Return on assets | −46.2% | −56.7% | −22.5% |
| Asset turnover | 0.00 | 0.00 | 0.00 |
| Current ratio | 7.46 | 15.84 | 12.81 |
| Debt to equity | — | 0.9% | 1.4% |
| Interest cover (operating income ÷ interest) | — | — | n/m |
| R&D as % of revenue | >999% | >999% | >999% |
| Capital spending as % of revenue | >999% | >999% | >999% |
| Quarter | 2021 Q1Mar 2021 | 2021 Q2Jun 2021 | 2021 Q3Sept 2021 | 2021 Q4Dec 2021 | 2022 Q1Mar 2022 | 2022 Q2Jun 2022 | 2022 Q3Sept 2022 | 2022 Q4Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | >999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Current ratio | — | 5.44 | 20.68 | 15.84 | 17.48 | 14.86 | 13.41 | 12.81 |
| Debt to equity | — | — | 0.9% | 0.9% | — | — | — | — |
| R&D as % of revenue | >999% | >999% | >999% | >999% | >999% | >999% | >999% | >999% |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
More: Biotechnology stocks compared, Health Care sector, rankings of US companies